Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Roche reports sales growth as new drugs ease pressure from biosimilar competition
  2. AstraZeneca to continue UK investment freeze due to Brexit uncertainty
  3. The highs and lows of hormone replacement therapy
  4. Gene and cell therapies: making manufacturing work
  5. Patient death following CAR-T therapy highlights serious manufacturing issues

Latest Content

How will the UK’s relaxed cannabis regulations impact clinical practice?

The UK home secretary announced that as of November 1, specialist doctors will be given the option to legally prescribe patients cannabis-based products if their patients would benefit from the treatment. This will stop regulations from limiting the disease indications that cannabis-based medicines can be prescribed for, and physicians will no longer need to seek approval from an expert panel for patients to access these medicines.

Biopharmaceuticals and Liposomal Formulations

Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients and vaccine antigens. A broad spectrum of analytical methods has been established for this purpose.

The New HOF smartVTS Vial Transfer System

The demand for high-quality loading and unloading systems for freeze-drying systems in the pharmaceutical and biotechnological industries is increasing. HOF fulfils this need with the right innovative answers and the expansion of reliable and high-quality production.

Sepha Multi-Q Leak Testing System

The Sepha Multi-Q is a standalone, multi-functional, non-destructive leak test system that can be used in combination with interchangeable attachments to fit the full range of container types available on the market today.

Trial design should give Dermira’s AD drug a better shot at Phase IIb success

Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top